Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

被引：0

作者：

Eberhardt, W. E. E. ^{[1
]}

Johnson, B. E. ^{[2
]}

Sun, Y. ^{[3
]}

Germonpre, P. ^{[4
]}

Saijo, N. ^{[5
]}

Zhou, C. ^{[6
]}

Wang, J. ^{[7
]}

Tada, H. ^{[8
]}

Kennedy, S. ^{[9
]}

Herbst, R. S. ^{[10
]}

机构：

[1] Univ Duisburg Essen, German Tumor Ctr, Essen, Germany

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Canc Hosp, Beijing, Peoples R China

[4] Univ Antwerp Hosp, Antwerp, Belgium

[5] Natl Canc Ctr Hosp E, Chiba, Japan

[6] Tongji Univ, Shanghai 200092, Peoples R China

[7] Beijing Inst Canc Res, Beijing, Peoples R China

[8] AstraZeneca, Med Sci, Wilmington, DE USA

[9] AstraZeneca, Biostat, Macclesfield, Cheshire, England

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71714-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：505 / 505

页数：1